Effects of the Combined Therapy with Raloxifene and Low-Dose Intermittent Fluoride for Two Years in Postmenopausal Women with Osteoporosis.
- Author:
Suk Mo CHUNG
1
;
Ghi Chan KIM
Author Information
1. Department of Physical Medicine and Rehabilitation, Kosin University College of Medicine, Korea. jeesang77@hanmail.net
- Publication Type:Original Article
- Keywords:
Postmenopausal osteoporosis;
Raloxifene;
Fluoride
- MeSH:
Bone Density;
Cholesterol;
Cholesterol, HDL;
Cholesterol, LDL;
Female;
Femur;
Fluorides*;
Humans;
Lipid Metabolism;
Osteocalcin;
Osteoporosis*;
Osteoporosis, Postmenopausal;
Raloxifene Hydrochloride*;
Spine;
Triglycerides
- From:Journal of the Korean Academy of Rehabilitation Medicine
2007;31(2):207-212
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: To compare the effects of raloxifene alone with a combination of raloxifene and fluoride in postmenopausal osteoporosis on bone mineral density, bone turnover and lipid profiles, at 2 year. METHOD: Fifty two women with postmenopausal osteoporosis (T-score < 2.5) were studied. Subjects were divided into two groups; Group I (n=23), treated with raloxifene and fluoride, and Group II (n=29), treated with raloxifene alone. Bone mineral density (BMD) at the lumbar spine and femur, osteocalcin, deoxypyridinoline and lipid profiles were measured at baseline and 2 years after treatment. RESULTS: BMD at the lumbar spine was increased in two groups, and BMD in Group I was increased more than that in Group II. Osteocalcin was increased in Group I, and was decreased in Group II. Deoxypyridinoline was decreased in two groups. Total cholesterol and LDL cholesterol were decreased in two groups, but HDL cholesterol and triglyceride showed no significant change in two groups. There were no significant differences between two groups in lipid profiles. CONCLUSION: The combined therapy with raloxifene and low- dose intermittent fluoride was more effective in postmenopausal women with osteoporosis than raloxifene alone, which would not influence on positive effect of raloxifene for lipid metabolism.
